

Nigel Russell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11085984/publications.pdf>

Version: 2024-02-01

12
papers

2,292
citations

840776

11
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

2849
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Minimal Residual Disease in Standard-Risk AML. <i>New England Journal of Medicine</i> , 2016, 374, 422-433.	27.0	662
2	Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. <i>Blood</i> , 2002, 100, 4310-4316.	1.4	381
3	Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). <i>Blood</i> , 2012, 119, 3361-3369.	1.4	355
4	The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 579-590.	27.6	352
5	Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. <i>Haematologica</i> , 2009, 94, 230-238.	3.5	161
6	Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 385-390.	2.0	151
7	Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1419-1427.	2.0	93
8	Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. <i>Haematologica</i> , 2010, 95, 989-995.	3.5	71
9	How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML). <i>British Journal of Haematology</i> , 2021, 193, 231-244.	2.5	31
10	Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?. <i>British Journal of Haematology</i> , 2020, 188, 86-100.	2.5	17
11	Analysis of the clinical impact of <i>NPM1</i> mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 852-859.	2.5	13
12	Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Campath Allogeneic Stem Cell Transplantation for Aggressive Non-Hodgkin Lymphoma: An Analysis of Outcomes from the British Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 483-488.	2.0	5